Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Thomas J Hwang

Title
Institution
Department
Address

Biography
Harvard Medical SchoolM.D.
Harvard CollegeA.B.

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Hwang TJ, Brawley OW. New Federal Incentives for Diversity in Clinical Trials. N Engl J Med. 2022 10 13; 387(15):1347-1349. PMID: 36214598.
    Citations:    Fields:    Translation:Humans
  2. Hwang TJ, Kesselheim AS, Dusetzina SB. Reforming Patient Cost Sharing for Cancer Medications in Medicare Part D. JAMA Oncol. 2022 10 01; 8(10):1398-1400. PMID: 35925591.
    Citations:    Fields:    Translation:Humans
  3. Hwang TJ, Kesselheim AS, Rome BN. New Reforms to Prescription Drug Pricing in the US: Opportunities and Challenges. JAMA. 2022 09 20; 328(11):1041-1042. PMID: 35984652.
    Citations:    Fields:    
  4. Vokinger KN, Kesselheim AS, Glaus CEG, Hwang TJ. Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021. JAMA Health Forum. 2022 08 05; 3(8):e222685. PMID: 36200635; PMCID: PMC9391955.
    Citations:    Translation:Humans
  5. Hwang TJ, Bourgeois FT. New legislation to promote paediatric studies for new cancer medicines. Lancet Oncol. 2022 08; 23(8):e368-e369. PMID: 35901829.
    Citations:    Fields:    
  6. Hwang TJ, Trinh QD, Tibau A, Vokinger KN. Reforms to accelerated approval of new medicines: long overdue. Lancet. 2022 07 30; 400(10349):357-358. PMID: 35835129.
    Citations:    Fields:    
  7. Hwang TJ, Isaac-Wilkins S, Trinh QD. Trends in Launch Prices and Price Increases for New Medicines for Urological Cancers. J Urol. 2022 09; 208(3):514-516. PMID: 35757920.
    Citations:    Fields:    
  8. Hwang TJ, Kesselheim AS, Tibau A, Lee CC, Vokinger KN. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. JCO Oncol Pract. 2022 09; 18(9):e1522-e1532. PMID: 35731996; PMCID: PMC9509186.
    Citations:    Fields:    
  9. Naci H, Kyriopoulos I, Feldman WB, Hwang TJ, Kesselheim AS, Chandra A. Coverage of New Drugs in Medicare Part D. Milbank Q. 2022 06; 100(2):562-588. PMID: 35502786; PMCID: PMC9205672.
    Citations:    Fields:    Translation:Humans
  10. Vokinger KN, Hwang TJ, Glaus CEG, Kesselheim AS. Therapeutic Value Assessments of Novel Medicines in the US and Europe, 2018-2019. JAMA Netw Open. 2022 04 01; 5(4):e226479. PMID: 35385091; PMCID: PMC8987900.
    Citations: 3     Fields:    Translation:Humans
  11. Vokinger KN, Hwang TJ, Carl DL, Laube Y, Ludwig WD, Naci H, Kesselheim AS. Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis. Lancet Oncol. 2022 04; 23(4):514-520. PMID: 35271804.
    Citations: 2     Fields:    Translation:Humans
  12. Hwang TJ, Feng J, Maini L, Kesselheim AS. Medicaid Expenditures and Estimated Rebates on Line Extension Drugs, 2010-2018. J Gen Intern Med. 2022 11; 37(14):3769-3771. PMID: 35194743; PMCID: PMC9585137.
    Citations:    Fields:    
  13. Hwang TJ, Vokinger KN. New EU regulation on health technology assessment of cancer medicines. Lancet Oncol. 2022 02; 23(2):e58. PMID: 35114127.
    Citations: 2     Fields:    Translation:Humans
  14. Hwang TJ, Vokinger KN, Kesselheim AS. New Treatments for Migraine-Therapeutic Ratings and Comparative Coverage in the US, Canada, and Europe. JAMA Intern Med. 2022 02 01; 182(2):101-102. PMID: 34901995.
    Citations:    Fields:    Translation:Humans
  15. Hwang TJ, Qin X, Keating NL, Huskamp HA, Dusetzina SB. Assessment of Out-of-Pocket Costs With Rebate Pass-through for Brand-name Cancer Drugs Under Medicare Part D. JAMA Oncol. 2022 01 01; 8(1):155-156. PMID: 34762097; PMCID: PMC8587215.
    Citations:    Fields:    Translation:Humans
  16. Bujosa A, Moltó C, Hwang TJ, Tapia JC, Vokinger KN, Templeton AJ, Gich I, Barnadas A, Amir E, Tibau A. Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period. J Natl Compr Canc Netw. 2021 Sep 24; 1-9. PMID: 34560672.
    Citations: 1     Fields:    
  17. Vokinger KN, Hwang TJ, Daniore P, Lee CC, Tibau A, Grischott T, Rosemann TJ, Kesselheim AS. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe. JAMA Oncol. 2021 Sep 01; 7(9):e212026. PMID: 34196656; PMCID: PMC8251654.
    Citations: 3     Fields:    Translation:Humans
  18. Kesselheim AS, Hwang TJ, Avorn J. Paying for Prescription Drugs in the New Administration. JAMA. 2021 03 02; 325(9):819-820. PMID: 33651097.
    Citations: 1     Fields:    Translation:Humans
  19. Hwang TJ, Ross JS, Vokinger KN, Kesselheim AS. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. BMJ. 2020 10 07; 371:m3434. PMID: 33028575; PMCID: PMC7537471.
    Citations: 6     Fields:    Translation:Humans
  20. Carmack M, Hwang T, Bourgeois FT. Pediatric Drug Policies Supporting Safe And Effective Use Of Therapeutics In Children: A Systematic Analysis. Health Aff (Millwood). 2020 10; 39(10):1799-1805. PMID: 33017255.
    Citations: 2     Fields:    Translation:Humans
  21. Hwang TJ, Randolph AG, Bourgeois FT. Inclusion of Children in Clinical Trials of Treatments for Coronavirus Disease 2019 (COVID-19). JAMA Pediatr. 2020 Sep 01; 174(9):825-826. PMID: 32379296.
    Citations: 11     Fields:    Translation:HumansPHPublic Health
  22. Molto C, Hwang TJ, Borrell M, Andres M, Gich I, Barnadas A, Amir E, Kesselheim AS, Tibau A. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration. Cancer. 2020 10 01; 126(19):4390-4399. PMID: 32697362.
    Citations: 3     Fields:    Translation:Humans
  23. Vokinger KN, Hwang TJ, Grischott T, Reichert S, Tibau A, Rosemann T, Kesselheim AS. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. Lancet Oncol. 2020 05; 21(5):664-670. PMID: 32359489.
    Citations: 30     Fields:    Translation:Humans
  24. Hwang TJ, Orenstein L, DuBois SG, Janeway KA, Bourgeois FT. Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers. J Natl Cancer Inst. 2020 03 01; 112(3):224-228. PMID: 31665394.
    Citations: 5     Fields:    Translation:Humans
  25. Hwang TJ, Kesselheim AS, Vokinger KN. Lifecycle Regulation of Artificial Intelligence- and Machine Learning-Based Software Devices in Medicine. JAMA. 2019 12 17; 322(23):2285-2286. PMID: 31755907.
    Citations: 31     Fields:    Translation:Humans
  26. Neez E, Hwang TJ, Sahoo SA, Naci H. European Medicines Agency's Priority Medicines Scheme at 2 Years: An Evaluation of Clinical Studies Supporting Eligible Drugs. Clin Pharmacol Ther. 2020 03; 107(3):541-552. PMID: 31591708.
    Citations: 5     Fields:    Translation:Humans
  27. Hwang TJ, Sinha MS, Dave CV, Kesselheim AS. Prescription Opioid Epidemic and Trends in the Clinical Development of New Pain Medications. Mayo Clin Proc. 2019 12; 94(12):2437-2443. PMID: 31685265.
    Citations:    Fields:    Translation:HumansPHPublic Health
  28. Hwang TJ, Dusetzina SB, Feng J, Maini L, Kesselheim AS. Price Increases of Protected-Class Drugs in Medicare Part D, Relative to Inflation, 2012-2017. JAMA. 2019 07 16; 322(3):267-269. PMID: 31310287.
    Citations: 8     Fields:    
  29. Beall RF, Hwang TJ, Kesselheim AS. Pre-market development times for biologic versus small-molecule drugs. Nat Biotechnol. 2019 07; 37(7):708-711. PMID: 31213674.
    Citations: 6     Fields:    Translation:Humans
  30. Gyawali B, Hwang TJ, Vokinger KN, Booth CM, Amir E, Tibau A. Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:374-387. PMID: 31099613.
    Citations: 8     Fields:    Translation:Humans
  31. Hwang TJ, Vokinger KN, Sachs RE. Evaluating New Rules on Transparency in Cancer Research and Drug Development. JAMA Oncol. 2019 Apr 01; 5(4):461-462. PMID: 30789629.
    Citations: 1     Fields:    Translation:Humans
  32. Beall RF, Hwang TJ, Kesselheim AS. Major Events in the Life Course of New Drugs, 2000-2016. N Engl J Med. 2019 Mar 14; 380(11):e12. PMID: 30865793.
    Citations: 1     Fields:    
  33. Hwang TJ, Jain N, Lauffenburger JC, Vokinger KN, Kesselheim AS. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs. JAMA Intern Med. 2019 03 01; 179(3):374-380. PMID: 30640379; PMCID: PMC6439690.
    Citations: 5     Fields:    Translation:Humans
  34. Hwang TJ, Bourgeois FT, Franklin JM, Kesselheim AS. Impact Of The Priority Review Voucher Program On Drug Development For Rare Pediatric Diseases. Health Aff (Millwood). 2019 02; 38(2):313-319. PMID: 30715972.
    Citations: 5     Fields:    Translation:Humans
  35. Hwang TJ, Orenstein L, Kesselheim AS, Bourgeois FT. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act. JAMA Pediatr. 2019 01 01; 173(1):68-74. PMID: 30452498; PMCID: PMC6583440.
    Citations: 14     Fields:    Translation:Humans
  36. Hwang TJ, Gyawali B. Association between progression-free survival and patients' quality of life in cancer clinical trials. Int J Cancer. 2019 04 01; 144(7):1746-1751. PMID: 30374970.
    Citations: 18     Fields:    Translation:Humans
  37. Hwang TJ, Kesselheim AS, Gyawali B. Affordability and Price Increases of New Cancer Drugs in Clinical Guidelines, 2007-2016. JNCI Cancer Spectr. 2018 Apr; 2(2):pky016. PMID: 31360849.
    Citations: 2     Fields:    
  38. Pregelj L, Hwang TJ, Hine DC, Siegel EB, Barnard RT, Darrow JJ, Kesselheim AS. Precision Medicines Have Faster Approvals Based On Fewer And Smaller Trials Than Other Medicines. Health Aff (Millwood). 2018 05; 37(5):724-731. PMID: 29733717.
    Citations: 6     Fields:    Translation:Humans
  39. Sinha MS, Jain N, Hwang T, Kesselheim AS. Expansion of the Priority Review Voucher Program Under the 21st Century Cures Act: Implications for Innovation and Public Health. Am J Law Med. 2018 May; 44(2-3):329-341. PMID: 30106661.
    Citations:    Fields:    Translation:Humans
  40. Hwang TJ, Franklin JM, Chen CT, Lauffenburger JC, Gyawali B, Kesselheim AS, Darrow JJ. Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines. J Clin Oncol. 2018 06 20; 36(18):1805-1812. PMID: 29688832.
    Citations: 16     Fields:    Translation:Humans
  41. Hwang TJ, Tomasi PA, Saint-Raymond A, Bourgeois FT. Availability of paediatric information in European Medicines Agency approvals. Lancet Child Adolesc Health. 2018 05; 2(5):e9. PMID: 30169272.
    Citations: 1     Fields:    Translation:Humans
  42. Hwang TJ, Tomasi PA, Bourgeois FT. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study. PLoS Med. 2018 03; 15(3):e1002520. PMID: 29494592; PMCID: PMC5832187.
    Citations: 11     Fields:    Translation:Humans
  43. Sinha MS, Freifeld CC, Brownstein JS, Donneyong MM, Rausch P, Lappin BM, Zhou EH, Dal Pan GJ, Pawar AM, Hwang TJ, Avorn J, Kesselheim AS. Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis. JMIR Public Health Surveill. 2018 Jan 05; 4(1):e1. PMID: 29305342.
    Citations: 7     
  44. Bourgeois FT, Hwang TJ. Improving the Study of New Medicines for Children With Rare Diseases. JAMA Pediatr. 2018 Jan 01; 172(1):7-9. PMID: 29131900.
    Citations: 3     Fields:    Translation:Humans
  45. Hwang TJ, Darrow JJ, Kesselheim AS. The FDA's Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016. JAMA. 2017 12 05; 318(21):2137-2138. PMID: 29209711; PMCID: PMC5820715.
    Citations: 16     Fields:    
  46. Hwang TJ, Kesselheim AS, Sarpatwari A. Value-Based Pricing and State Reform of Prescription Drug Costs. JAMA. 2017 08 15; 318(7):609-610. PMID: 28692713.
    Citations: 8     Fields:    
  47. Jain N, Hwang T, Franklin JM, Kesselheim AS. Association of the Priority Review Voucher With Neglected Tropical Disease Drug and Vaccine Development. JAMA. 2017 07 25; 318(4):388-389. PMID: 28742898; PMCID: PMC5817607.
    Citations: 7     Fields:    Translation:Humans
  48. Hwang TJ, Kesselheim AS. Challenges in the Development of Novel Cardiovascular Therapies. Clin Pharmacol Ther. 2017 Aug; 102(2):194-196. PMID: 28643861.
    Citations: 3     Fields:    Translation:Humans
  49. Hwang TJ, Franklin JM, Kesselheim AS. Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development. Clin Pharmacol Ther. 2017 Aug; 102(2):290-296. PMID: 28390139.
    Citations: 2     Fields:    Translation:Humans
  50. Davies BJ, Hwang TJ, Kesselheim AS. Ensuring Access to Injectable Generic Drugs - The Case of Intravesical BCG for Bladder Cancer. N Engl J Med. 2017 Apr 13; 376(15):1401-1403. PMID: 28402764.
    Citations: 16     Fields:    Translation:Humans
  51. Bourgeois FT, Hwang TJ. The Pediatric Research Equity Act Moves Into Adolescence. JAMA. 2017 01 17; 317(3):259-260. PMID: 28114560.
    Citations: 13     Fields:    Translation:Humans
  52. Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, Kesselheim AS. Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. JAMA Intern Med. 2016 Dec 01; 176(12):1826-1833. PMID: 27723879.
    Citations: 82     Fields:    Translation:Humans
  53. Hwang TJ, Kesselheim AS. Public referendum on drug prices in the US: will it bring relief? BMJ. 2016 Oct 31; 355:i5657. PMID: 27799143.
    Citations: 1     Fields:    Translation:Humans
  54. Hwang TJ, LaMattina JL. Measuring the Value of New Medications and Implications for Medicare's Proposed Part B Drug Payment Model. JAMA Oncol. 2016 Sep 01; 2(9):1125-6. PMID: 27388928.
    Citations: 1     Fields:    Translation:Humans
  55. Hwang TJ, Lauffenburger JC, Franklin JM, Kesselheim AS. Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012. JACC Basic Transl Sci. 2016 Aug; 1(5):301-308. PMID: 30167520; PMCID: PMC6113354.
    Citations: 8     
  56. Hwang TJ, Sokolov E, Franklin JM, Kesselheim AS. Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort study. BMJ. 2016 Jun 28; 353:i3323. PMID: 27352914; PMCID: PMC4925918.
    Citations: 11     Fields:    Translation:HumansPHPublic Health
  57. Hwang TJ, Kesselheim AS. Leveraging Novel and Existing Pathways to Approve New Therapeutics to Treat Serious Drug-Resistant Infections. Am J Law Med. 2016 05; 42(2-3):429-450. PMID: 29086648.
    Citations: 1     Fields:    Translation:Humans
  58. Hwang TJ, Kesselheim AS. Vaccine Pipeline Has Grown During The Past Two Decades With More Early-Stage Trials From Small And Medium-Size Companies. Health Aff (Millwood). 2016 Feb; 35(2):219-26. PMID: 26858373.
    Citations: 1     Fields:    Translation:Humans
  59. Kesselheim AS, Hwang TJ. Breakthrough Medical Devices and the 21st Century Cures Act. Ann Intern Med. 2016 Apr 05; 164(7):500-2. PMID: 26785350.
    Citations: 5     Fields:    Translation:HumansPHPublic Health
  60. Kesselheim AS, Hwang TJ, Franklin JM. Two decades of new drug development for central nervous system disorders. Nat Rev Drug Discov. 2015 Dec; 14(12):815-6. PMID: 26585536.
    Citations: 36     Fields:    Translation:Humans
  61. Hwang TJ, Gibbs KA, Podolsky SH, Linder JA. Antimicrobial stewardship and public knowledge of antibiotics. Lancet Infect Dis. 2015 Sep; 15(9):1000-1001. PMID: 26333323.
    Citations: 5     Fields:    Translation:Humans
  62. Hwang J, Hwang TJ, Ciolino JB. Pivotal clinical trials of novel ophthalmic drugs and medical devices: retrospective observational study, 2002-2012. BMJ Open. 2015 Jun 04; 5(6):e007987. PMID: 26044760.
    Citations: 1     Fields:    Translation:Humans
  63. Hwang TJ, Powers JH, Carpenter D, Kesselheim AS. Accelerating innovation in rapid diagnostics and targeted antibacterials. Nat Biotechnol. 2015 Jun; 33(6):589-90. PMID: 26057972.
    Citations: 3     Fields:    Translation:Humans
  64. Hwang TJ, Lehmann LS, Kesselheim AS. Precision medicine and the FDA's draft guidance on laboratory-developed tests. Nat Biotechnol. 2015 May; 33(5):449-51. PMID: 25965745.
    Citations: 3     Fields:    Translation:Humans
  65. Hwang TJ, Ciolino JB. Retinal implants and Medicare reimbursement policies for breakthrough treatments in ophthalmology. JAMA Ophthalmol. 2015 Apr; 133(4):373-4. PMID: 25675029; PMCID: PMC8519350.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  66. Hwang TJ, Kiang C, Paul M. Surgical applications of 3-dimensional printing and precision medicine. JAMA Otolaryngol Head Neck Surg. 2015 Apr; 141(4):305-6. PMID: 25695233.
    Citations: 4     Fields:    Translation:HumansPHPublic Health
  67. Hwang TJ, Carpenter D, Kesselheim AS. Paying for innovation: reimbursement incentives for antibiotics. Sci Transl Med. 2015 Feb 25; 7(276):276fs9. PMID: 25717095.
    Citations: 4     Fields:    Translation:Humans
  68. Hwang TJ, Bourgeois FT. New regulatory paradigms for innovative drugs to treat pediatric diseases. JAMA Pediatr. 2014 Oct; 168(10):879-80. PMID: 25111315; PMCID: PMC4741094.
    Citations: 1     Fields:    Translation:Humans
  69. Hwang TJ, Keshavjee S. Global financing and long-term technical assistance for multidrug-resistant tuberculosis: scaling up access to treatment. PLoS Med. 2014 Sep; 11(9):e1001738. PMID: 25268235.
    Citations: 2     Fields:    Translation:Humans
  70. Hwang TJ, Bourgeois FT, Seeger JD. Drug safety in the digital age. N Engl J Med. 2014 Jun 26; 370(26):2460-2. PMID: 24963564.
    Citations: 5     Fields:    Translation:Humans
  71. Hwang TJ, Carpenter D, Kesselheim AS. Target small firms for antibiotic innovation. Science. 2014 May 30; 344(6187):967-9. PMID: 24876477.
    Citations: 4     Fields:    Translation:Humans
  72. Hwang TJ, Avorn J, Kesselheim AS. Life cycle of medical product rules issued by the US Food and Drug Administration. J Health Polit Policy Law. 2014 Aug; 39(4):751-80. PMID: 24842974.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  73. Hwang TJ, Kesselheim AS, Bourgeois FT. Postmarketing trials and pediatric device approvals. Pediatrics. 2014 May; 133(5):e1197-202. PMID: 24733871; PMCID: PMC4531281.
    Citations: 15     Fields:    Translation:HumansPHPublic Health
  74. Hwang TJ, Hooper DC. Association between fluoroquinolone resistance and resistance to other antimicrobial agents among Escherichia coli urinary isolates in the outpatient setting: a national cross-sectional study. J Antimicrob Chemother. 2014 Jun; 69(6):1720-2. PMID: 24521853.
    Citations: 4     Fields:    Translation:HumansCells
  75. Hwang TJ, Avorn J, Carpenter D, Kesselheim AS. Quantifying The Food And Drug Administration's rulemaking delays highlights the need for transparency. Health Aff (Millwood). 2014 Feb; 33(2):309-15. PMID: 24493775.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  76. Hwang TJ, Carpenter D, Kesselheim AS. Assessment of US pathway for approving medical devices for rare conditions. BMJ. 2014 Jan 17; 348:g217. PMID: 24443478.
    Citations: 7     Fields:    Translation:HumansPHPublic Health
  77. Hwang TJ, Dotsenko S, Jafarov A, Weyer K, Falzon D, Lunte K, Nunn P, Jaramillo E, Keshavjee S, Wares DF. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open. 2014 Jan 02; 4(1):e004143. PMID: 24384902; PMCID: PMC3902362.
    Citations: 17     Fields:    Translation:Humans
  78. Hwang TJ. Stock market returns and clinical trial results of investigational compounds: an event study analysis of large biopharmaceutical companies. PLoS One. 2013; 8(8):e71966. PMID: 23951273.
    Citations: 6     Fields:    Translation:Humans
  79. Hwang TJ, Wares DF, Jafarov A, Jakubowiak W, Nunn P, Keshavjee S. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis. Int J Tuberc Lung Dis. 2013 Oct; 17(10):1257-66. PMID: 23735593.
    Citations: 32     Fields:    Translation:Humans
  80. Hwang TJ, Ottmani S, Uplekar M. A rapid assessment of prevailing policies on tuberculosis contact investigation. Int J Tuberc Lung Dis. 2011 Dec; 15(12):1620-3. PMID: 22118168.
    Citations: 26     Fields:    Translation:HumansPHPublic Health
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Hwang's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (205)
Explore
_
Co-Authors (23)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.